# Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.

> **NCT00422422** · PHASE2 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 100 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Brivaracetam

## Key facts

- **NCT ID:** NCT00422422
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2018-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00422422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00422422, "Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00422422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*